Lixoft Revenue and Competitors
Estimated Revenue & Valuation
- Lixoft's estimated annual revenue is currently $2.1M per year.
- Lixoft's estimated revenue per employee is $101,500
Employee Data
- Lixoft has 21 Employees.
- Lixoft grew their employee count by 17% last year.
Lixoft's People
Name | Title | Email/Phone |
---|
Lixoft Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $57.6M | 318 | 24% | N/A | N/A |
#2 | $44.6M | 286 | 23% | $25.4M | N/A |
#3 | $5.1M | 44 | -6% | N/A | N/A |
#4 | $35.1M | 225 | -3% | $46.9M | N/A |
#5 | $14.5M | 100 | 5% | N/A | N/A |
#6 | $1.3M | 15 | -6% | N/A | N/A |
#7 | $1.5M | 17 | 0% | N/A | N/A |
#8 | $2.9M | 29 | -12% | N/A | N/A |
#9 | $125.2M | 691 | 6% | N/A | N/A |
#10 | $95.9M | 529 | -1% | N/A | N/A |
What Is Lixoft?
Lixoft develops modeling and simulation software for advanced model-based drug development, and offers powerful and easy solutions for population analysis in pre-clinical and clinical trials, pharmacovigilance and pharmacoepidemiology. Lixoft allows the deployment of the most advanced mathematical models in pharmacology, by combining breakthough statistical methods with unique ease of use. The Lixoft products advance translational medicine with communication-enabling tools for a shared ownership all across the drug development continuum.
keywords:N/AN/A
Total Funding
21
Number of Employees
$2.1M
Revenue (est)
17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Lixoft News
It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. Featured Articles. Get a free copy of the StockNews.com...
Jonathan Chauvin, President of the Lixoft division at Simulations Plus, said: Our efficient NCA calculation engine in PKanalix, with our...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $9.9M | 40 | 11% | N/A |
#2 | N/A | 44 | 29% | N/A |
#3 | N/A | 118 | 22% | N/A |
#4 | $37M | 137 | 6% | N/A |
#5 | $37.1M | 148 | 19% | N/A |